BDBM652473 5-N-[(6-{5H,6H,8H-imidazo[1,2-a]piperazin-7-yl}pyridin-3-yl)methyl]isoquinoline-1,5- diamine::US20240059691, Example 1128

SMILES Nc1nccc2c(NCc3ccc(nc3)N3CCn4ccnc4C3)cccc12

InChI Key InChIKey=YCUHYXGBQOXOJG-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 652473   

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 650nMAssay Description:In vitro inhibition of Factor XIIa was determined using an IC50 assay based on standard literature methods (see e.g Baeriswyl et al., ACS Chem. Biol....More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 6.50E+3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 2.50E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasminogen(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetSerine protease 1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652473(US20240059691, Example 1128 | 5-N-[(6-{5H,6H,8H-im...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent